Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, discusses patient selection for time-limited and continuous therapy in chronic lymphocytic leukemia (CLL). While data from the GAIA/CLL13 study (NCT02950051) has demonstrated that patients with mutated IGHV status benefit more from time-limited therapy, it has been suggested that high-risk or very high-risk patients have better responses with continuous treatment. For patients with some adverse prognostic factors, Dr Eichhorst emphasizes the importance of shared treatment decision-making. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.